top of page
1/2
Pioneering Novel Genetic Medicines for Cardiomyopathies
Our Mission
At Nuevocor, our mission is to revolutionize the treatment of untreatable cardiomyopathies by embracing a mechanobiology-centered approach.
These conditions represent a pressing medical challenge, striking individuals at a relatively young age and leads to heart failure. Presently, the only recourse for these patients is a costly and often elusive cardiac transplant.
About Us
With operations in both the United States and Singapore, Nuevocor focuses on treating heart conditions known as genetic cardiomyopathies by addressing their underlying mechanical defects.
Nuevocor’s lead program NVC-001 is a genetic medicine to treat patients suffering from lamin-related dilated cardiomyopathy.
News
27 September 2024
Nuevocor will present and participate in a panel discussion at the Chardan’s 8th Annual Genetic Medicines Conference – New York City – September 30 - October 1, 2024
We are pleased to share that our Chief Executive Officer and co-founder, Dr. Yann Chong Tan, and our Chief Medical Officer, Dr. John Lee, are attending #Chardan’s invite-only 8th Annual Genetic Medicines Conference held at The Westin Grand Central, New York City from September 30 to October 1, 2024, where we will give a presentation on Nuevocor on 1 October 2024 from 2.30PM to 3.00PM.
18 September 2024
Nuevocor won Most Promising Gene Therapy Pipeline in APAC at the Asia Pacific Cell & Gene Therapy Excellence Awards 2024 through public voting
We are pleased to announce that we won the Most Promising Gene Therapy Pipeline in APAC at the Asia Pacific Cell & Gene Therapy Excellence Awards 2024. Winners are decided through voting by the public.
bottom of page